US 11,129,890 B1 · Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein

Abstract

The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface (“SARS-CoV-2 S Protein Lentiviral Particles”), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to “SARS-CoV-2 S Protein Lentiviral Vaccine” pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles. The present invention is additionally directed to the use of such SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions for providing immunity to COVID-19 infection to humans and other mammals, either directly or as an inactivated form.

Claims22

Dependent claims

A lentiviral particle that:

(A) comprises:
(1) a recombinantly engineered HIV-1 vector that comprises, in the 5′ to 3′ direction:
(a) a human cytomegalovirus (CMV) immediate early enhancer site and promoter;
(b) an HIV-1 5′ LTR region that has been truncated to delete its U3 region;
(c) an HIV-1 ψ region;
(d) an HIV-1 Rev response element (RRE);
(e) an HIV-1 central polypurine tract and central termination sequence (cPPT/CTS);
(f) a heterologous enhancer and promoter;
(g) a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE);
and
(h) a self-inactivating HIV-1 3′ LTR region;
(2) a mutated HIV-1 integrase (IN) protein that is incapable of mediating the integration of said recombinantly engineered HIV-1 vector into the chromosome of a recipient cell;
and
(3) a mutated HIV-1 reverse transcriptase (RT) protein that is incapable of reverse transcribing said recombinantly engineered HIV-1 vector;
and
(B) arrays a SARS-CoV-2 spike (S) protein on its surface.

13 more elements

Dependencies are inferred from the claim text.

Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein

Life of this patent

Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein

Life of this patent

Abstract

Claims22